235 related articles for article (PubMed ID: 21045200)
1. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
[TBL] [Abstract][Full Text] [Related]
2. CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Jin Y; Zollinger M; Borell H; Zimmerlin A; Patten CJ
Drug Metab Dispos; 2011 Feb; 39(2):191-8. PubMed ID: 21045201
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of fingolimod phosphate in healthy participants.
Wu K; Mercier F; David OJ; Schmouder RL; Looby M
J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
[TBL] [Abstract][Full Text] [Related]
4. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
5. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
6. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA; Weinstock-Guttman B
Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR; Pearce CJ; Oberlies NH
J Nat Prod; 2011 Apr; 74(4):900-7. PubMed ID: 21456524
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
13. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
[TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
15. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of fingolimod.
David OJ; Kovarik JM; Schmouder RL
Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
[TBL] [Abstract][Full Text] [Related]
17. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat.
Patel DK; Woolley JL; Shcokcor JP; Johnson RL; Taylor LC; Sigel CW
Drug Metab Dispos; 1991; 19(2):491-7. PubMed ID: 1676660
[TBL] [Abstract][Full Text] [Related]
18. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
[TBL] [Abstract][Full Text] [Related]
19. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
